Quarterly report pursuant to Section 13 or 15(d)

Organization and Summary of Significant Accounting Policies - Additional Information (Detail)

v3.21.2
Organization and Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Organization And Summary Of Significant Accounting Policies [Line Items]        
Cash, cash equivalents, and marketable securities $ 200.7   $ 200.7  
Revenue | Credit Risk | Vertex Pharmaceuticals Inc        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Percentage of total revenues 2.00% 43.00% 13.00% 40.00%
Revenue | Credit Risk | Takeda Pharmaceuticals Inc        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Percentage of total revenues 85.00% 44.00% 72.00% 31.00%
Revenue | Credit Risk | BMS        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Percentage of total revenues 13.00% 0.00% 16.00% 0.00%
Other Assets        
Organization And Summary Of Significant Accounting Policies [Line Items]        
Restricted cash $ 3.7   $ 3.7